What is CTD-ILD?
CTD-ILD (connective tissue disease-associated interstitial lung disease) is a group of lung disorders characterized by inflammation and/or fibrosis of the lung parenchyma that occurs as a complication of systemic autoimmune rheumatic diseases, representing approximately 20% of all interstitial lung diseases. 1
Definition and Scope
CTD-ILD encompasses pulmonary involvement in patients with various autoimmune conditions. The most commonly affected connective tissue diseases include:
- Systemic sclerosis (SSc) - accounts for ~31% of CTD-ILD cases
- Rheumatoid arthritis (RA) - accounts for ~39% of CTD-ILD cases
- Idiopathic inflammatory myopathies (IIM) - including dermatomyositis, polymyositis, and antisynthetase syndrome
- Sjögren's syndrome
- Systemic lupus erythematosus
- Mixed connective tissue disease 1, 2
Clinical Significance and Prognosis
Progressive pulmonary fibrosis (PPF) represents the primary cause of death in patients with CTDs, alongside cardiovascular comorbidities. 1 The incidence of PPF in CTD-ILD is approximately 29%, causing irreversible lung damage, significant morbidity, and increased mortality 3. In systemic sclerosis specifically, ILD affects over 50% of adults and is the leading cause of death and hospitalization 2.
Clinical Presentation
The presentation varies considerably across CTD subtypes 1:
- Asymptomatic cases: Early, irreversible lung function loss can occur without symptoms
- Nonspecific symptoms: Fatigue, cough, or dyspnea on exertion that may be masked by other organ involvement (myopathy, cardiac disease)
- Progressive disease: Worsening fibrotic abnormalities, declining lung function, and respiratory failure 1, 4
Pathophysiology
CTD-ILD results from immune-mediated dysfunction causing alveolar inflammation and interstitial fibrosis. The pathogenic mechanism involves dysregulation of inflammatory pathways leading to lung fibroblast proliferation and activation, resulting in abnormal lung remodeling 5.
Key Clinical Challenge
A critical pitfall is delayed diagnosis—early but irreversible lung function loss frequently occurs before symptoms develop, while nonspecific respiratory complaints are often attributed to other CTD manifestations. 1 This underscores the importance of systematic screening in at-risk populations rather than waiting for symptomatic presentation.
Management Approach
CTD-ILD requires multidisciplinary collaboration between rheumatologists and pulmonologists 1. The condition demands both pulmonary and rheumatological perspectives simultaneously, as immunosuppression remains the mainstay of therapy for the underlying CTD, though evidence for its effectiveness in slowing ILD progression is limited 6.